What the business is, and whether it's a good one at a fair price.
Manufactures specialty chemicals across three core segments — Home Care, Personal Care & Pharma Chemicals (HPPC), Textile Specialty Chemicals (TSC) and Animal Health & Nutrition (AHN) — serving B2B customers in home care, personal care, pharma, textiles, agrochemicals, performance chemicals and animal nutrition. Runs two manufacturing plants at Silvassa and Dahej, with subsidiary Unitop Chemicals providing ethoxylation capacity, and has commissioned a new 5,000 MTPA blending facility in Thailand for Southeast Asian markets. A greenfield project in Saudi Arabia is in progress, with management indicating about 1.5 years from announcement to first kilo of production. Customers in 50+ countries are served, with a dedicated R&D centre in Navi Mumbai supporting an innovation pipeline of biosurfactants, NMMO, MDEA, spray-cooled powders and pharma formulations. The B2C consumer business is being exited while institutional cleaning is retained, with a steady-state 15% EBITDA margin targeted over 2-3 years via product-mix upgrade. Raw materials — primarily ethylene oxide and phenol — are the largest cost at 66.9% of revenue, while the Andheri office was sold and net debt reduced to Rs. 248 crore in Q1 FY27.
Measured from the filed financials, judged against its Specialty Chemicals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from ROSSARI BIOTECH LIMITED's filed financials and exchange disclosures
ROSSARI BIOTECH LIMITED is a Chemicals & Petrochemicals company listed on NSE and BSE, trading under the symbol ROSSARI.
Yes. Over the trailing twelve months ROSSARI BIOTECH LIMITED reported a net profit of ₹151 Cr on revenue of ₹2,550 Cr.
Yes. The dividend yield is 0.11% at the current price. It paid out 2% of its profit as dividend in FY26.
No. Debt stands at 0.31× equity, and it carries net debt of ₹333 Cr. That is lower than 34% of its 101 Specialty Chemicals peers.
On trailing P/E, ROSSARI BIOTECH LIMITED ranks 29 of 103 in Specialty Chemicals — cheaper than 73% of them, against an industry median of 23.4×. This is a position, not a valuation judgement.
On a typical session ROSSARI BIOTECH LIMITED moves 1.13% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by ROSSARI BIOTECH LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
